

A year in review

BII IMPACT REPORT 2022

Bringing ideas to life
and research to market

BII BioInnovation
Institute



BII

BioInnovation
Institute

2018

First start-ups
joining BII

2019

Professor Jens Nielsen
appointed as CEO

2020

BII becomes an
independent foundation

2021

Start-ups at BII have raised
more than DKK 1 billion

2022

Transforming BII

Welcome

In the past year, BII has grown and expanded our offer to innovative entrepreneurs in the life science community, and the impact on the ecosystem is clear.

Throughout this report, you will find examples and read stories about our endeavors, but I would like to point out some of the achievements that I am particularly excited about.

In 2022, BII welcomed more start-ups and projects than ever before. With a 20 percent increase from 2021, we have now accepted a total of 80 projects and start-ups into our programs, and accumulatively our portfolio companies have raised ~EUR 240 million in additional funding since BII's inauguration in 2018. In 2022 alone, they raised ~EUR 90 million.

With the success of our portfolio companies, BII is beginning to significantly impact the life science ecosystem in Denmark by creating new jobs and attracting the interest of world leaders within life science philanthropy and industry. In 2022, we have among many others welcomed corporate-sponsored projects from Novo Nordisk and arranged many activities to strengthen the ecosystem within the area of women's health.

The academic community has also moved closer as we have launched the Bio Studio program. With this new program, we strive to build a leading life science-company creation facility in Europe. We have already welcomed projects from prestigious institutions such as EMBL, Imperial College

London, and the University of Washington, and when fully implemented, Bio Studio will run 15-20 top-level venture creation projects all run by experienced entrepreneurs in residence.

I am proud of the progress and impact we have achieved in 2022, and I am thankful for your continued support and partnership. I believe that together, we can drive the development of new solutions and ultimately, positively impact the societal challenges in human and planetary health around the world.

Prof. Jens Nielsen
Chief Executive Officer
BioInnovation Institute

“I believe that together, we can drive the development of new solutions and ultimately, positively impact the societal challenges in human and planetary health around the world.”

See Jens' reflections on 2022





BII

BioInnovation
Institute

BII

20%

Increase in projects and start-ups
in our programs 2021–2022

~EUR
98.5 million

Awarded in grants and
loans 2018–2022

~EUR
241.7 million

Funding raised by start-ups
2018–2022



290+

Jobs in Bio Studio projects and
start-ups by the end of 2022

9 Bio Studio projects
24 start-ups

supported in 2022

10 Bio Studio projects
70 start-ups

supported 2018–2022



BII team members look back at 2022

"At BII's Venture Lab program, we have created an attractive program for early-stage start-ups by having a founder-centric approach and a strong belief in the potential of academic entrepreneurs. In 2022 we experienced a growing interest in sustainable food production, green alternatives for the agricultural sector, and carbon capture technologies."

— **Maria Henriques De Jesus**
Senior Associate, BII



"In 2022, we launched our Women's Health Initiative to support innovation in women's health. Some of the highlights of the year include establishing a dedicated advisory panel of world-leading women's health experts, sourcing and enrolling new women's health projects and start-ups to our programs, and organizing an international ecosystem building event to raise awareness around the untapped potential of this important field with huge unmet needs."

— **Johanna Roostalu**
Principal, Womens Health, BII



"Our small legal team at BII has worked tirelessly during 2022 to optimize the legal processes surrounding our programs and for supporting the organization in setting up new initiatives, collaborations, and partnerships. Furthermore, it has been an exciting journey following the growth of the organization and the success stories of companies in the BII portfolio."

— **Johan Frederik Ehrenreich**
Legal Counsel, BII



"I am proud to have led a team that was passionately committed to spreading the word about our mission and impact through early-stage life science start-ups developing solutions that will benefit society. We are continuously aiming at keeping BII's goals and values at the forefront, and it is a privilege to be a part of BII's journey in bringing world-class life science innovation closer to the market."


— **Casper Linnemann**
Head of Communication, BII



An international life science institute.
We are here to help you bring your research to market.

Introducing BII's three focal points

To support life science start-ups and projects on their entrepreneurial journey, BII has chosen three focal points for continuous development and refinement.



Transforming our catalyst platform

BII is developing a platform that accelerates life science innovation from the very early stages and toward Series A investments. We continuously test, evaluate and shape our programs, and in 2022 we presented Venture House, which targets alumni from the early-stage program Venture Lab. In the Venture House program, the companies will further mature and de-risk to attract substantial funding.

In addition to the two Venture programs, BII supports world-leading scientists in translating academic research in the Bio Studio program. BII Residence is for life science companies that have raised substantial funding and are looking to join an entrepreneurial environment and expand their network.



Expanding our thriving portfolio

BII's funding, business development support, lab and office infrastructure and global network have allowed our portfolio to thrive and raise ~EUR 90 million in additional funding in 2022. In 2022, we welcomed 20 percent more start-ups and projects into our programs than in 2021, and our portfolio remains strong within both human and planetary health.

Broadening outreach, community & collaborations

BII is continuously building partnerships and collaborations with corporates and companies, universities and hospitals, investors and experts to create a strong foundation and community for our portfolio. This year, we have among others partnered with Novo Nordisk and Novozymes, and we have awarded the very first BII & Science Prize for Innovation in collaboration with the scientific journal *Science*.

The support from the Bill & Melinda Gates Foundation has also accelerated existing efforts and in 2022, BII introduced the Women's Health Innovation Panel to help bring forward innovation in women's health.



Transforming our
catalyst platform

Strengthening innovation in different stages

BII's new package of programs is set up to meet the needs from early acceleration to maturation towards Series A investment in the best possible way.


"Through our Venture programs, we have established a platform to accelerate early-stage start-ups towards Series A financing. Our founder-halos and crunches are crucial program elements that focus on developing more robust founders and ensuring a clear commercial focus."

— **Bobby Soni**
Chief Business Officer, BII



"Bio Studio is a Venture building program accelerating the development and commercialization of state-of-the-art research by partnering with leading research institutions and entrepreneurial academics. By insourcing world-class science projects, creating a robust project team, and adding BII facilities and network, we create a solid setup to create the next generation of life science start-ups and bioentrepreneurs."

— **Trine Bartholdy**
Chief Innovation Officer, BII




Venture Lab

Technology maturation level

Venture Lab

Assists early-stage start-ups over 12 months with interesting technology but an unclear path to the market.

Convertible loan of
~EUR 0.5 million




Venture House

Venture House

Supports start-ups with validated technology, well-defined IP and a clear path to market over 2 years to build an attractive case for Series A investors.

Convertible loan of
~EUR 1.3 million



Bio Studio

Bio Studio

Assists in translating world-class research into a company within 3 years by establishing a satellite group at BII that will form the basis of the future start-up company.

Grant of
~EUR 3 million



Residence

Residence

Residence offers innovative life science start-ups access to high-quality shared laboratory and office space in a vibrant, entrepreneurial community.

No funding



Transforming our
catalyst platform

Meet the passionate team

The overarching responsibility of the BII staff is to help increase the value of the start-up projects and to facilitate the journey from research to commercialisation for the teams in BII's programs.



BII

Gender balance

56%
Female



Age group

65%
Younger than 40



Citizenship

38%
International background



We work by three core values.
We call them the BII Basics.

Impactful

Catalytic

Passionate

BII has **66 staff members**
covering BII activities

"Having been with BII since its inception in 2018, I am incredibly proud to see how far we have come as an organization, the diversity of talent we comprise in relation to gender, age and background and how we cultivate and live our core values."

To be realized and fulfilled, these core values are integrated into every aspect of the BII employee journey, including recruitment, onboarding, daily interactions, internal collaboration, external collaboration, and performance evaluation and development."

— **Sofie Lorentzen**
Chief People Officer, BII







Transforming our
catalyst platform

More diverse applications

World-class science is found across the globe. Entrepreneurs from 31 countries submitted applications to BII in 2022. Around 50% came from outside Denmark, which is a +5% increase from 2021, indicating that BII has become more widely known.

31


166 applications from 31 countries
submitted to BII in 2022



33

9 Bio Studio projects and 24
start-ups were supported in 2022

20% increase in
projects and start-ups
from 2021–2022



2

Focus Areas

BII is dedicated to fostering innovation that will drive the creation of new technologies in the service of humanity and the earth, improving the health of the planet in order to support and supplement the focus on human health.

33% male
66% female




7



14

75% male
25% female



2



10



Transforming our
catalyst platform

New projects and start-ups in 2022

In 2022, BII grants and loans totalled EUR 28.9 million, supporting 33 new projects/start-ups in addition to three other projects and a grant. Total amount awarded 2018–2022: EUR 98.5 million.

"In Venture Lab we have a relatively large share of first-time entrepreneurs (52%) from different industries. Most are therapeutics related, reflecting the research base of where we are located in Copenhagen and Scandinavia with an abundance of excellent science relevant for therapeutics."

— Matthias Wulf
Senior Associate, BII



Movie 1



Movie 2



Movie 3



First-time
entrepreneurs in
Bio Studio projects
and start-ups in 2022
52%

Get more info



9 Bio Studio projects

ASAI - one of the Bio Studio projects

ASAI will deliver a transformative approach for early diagnostics and monitoring of highly debilitating diseases through the development of an ultrasensitive target-agnostic biosensing platform to inform clinical decisions with the aim of slowing disease progression and improving treatment plans.


Get more info



24 start-ups

ALGIECEL - one of the start-ups


ALGIECEL was founded to take part in solving the challenge of converting the CO₂ emissions of today's production methods into feasible business opportunities.



EUR
8.4million
Granted amount

9
Bio Studio
projects

5 projects have been
granted as part of the
Faculty program preceding
the Bio Studio program.




EUR
10.3million
Granted amount

133
Applications

17
Start-ups

12%
Approval rate



EUR
9.6million
Granted amount

33
Applications

7
Start-ups

21%
Approval rate



EUR
0.6million
Granted amount

4
Prizes and
other projects



Transforming our catalyst platform

Improving human and planetary health

To benefit people and society, BII supports life science innovation and solutions within two areas: human health and planetary health. Here are some of the projects and start-ups we welcomed into our programs.

Together with industry partners, BII focuses on applying the latest advances in biotechnology with the ultimate goal to leverage innovation in new and interesting ways to solve some of our greatest sustainability challenges.

Human Health



Fimmcyte

Fimmcyte is developing the first disease-modifying treatment for endometriosis to help relieve the millions of women affected by this painful disease.



Aiomic

Aiomic is developing the Surgical Advanced Warning (SAW) system to combat postoperative complications. An automated tracking and real-time risk assessment system for hospitals, a decision support tool for healthcare practitioners and an individualized patient empowerment tool for surgical candidates.



Ousia Pharma

Ousia Pharma is developing novel peptide-drug conjugates for treatment of obesity and metabolic diseases where peptides are used to deliver modulators of synaptic plasticity to drive a potent and sustained weight loss without compromising safety.



Planetary Health



Agrobiomics

Agrobiomics is solving food security and ensuring a sustainable and healthy food chain through the use of our biostimulant – a unique Streptomyces metabolite improving resilience of crops.

Nordic Virtual Pastures

Nordic Virtual Pastures introduces its ground-breaking 'Virtual Media' for the propagation of meat cells that through sustainability and at low cost will optimize the production and therefore allow the world to continue eating meat without the ethical and environmental issues that today surround the conventional meat industry.

Upstream Foods

Upstream Foods is introducing a novel ingredient to uplevel seafood alternatives. The start-up is using cell-culture methods, to make the absolutely tastiest fats that provide all the complex flavors, oily mouthfeel, and health benefits that people love about traditional seafood.





Transforming our
catalyst platform

Meet the start-ups

At BII, we welcome projects and start-ups led by both first-time and serial entrepreneurs into our programs. Here are three of the companies that joined us in 2022.



“Ousia Pharma develops novel peptide-drug conjugates for treating obesity and metabolic disease. We have identified specific pathways in the brain essential for appetite regulation and found a unique way to target those pharmacologically.”

We have had a fantastic learning experience at BII, taking significant leaps to exploit the commercial potential of our science, and the goal is to secure investments that will take us to the clinical evaluation of our lead candidate. Of course, science is the foundation, but there is an extra layer of necessity in communicating broadly, concisely, and with genuine passion.”

— Christoffer Clemmensen
CEO, Ousia Pharma



Get more info



“Algiecel was founded to solve the challenge of converting the CO₂ emissions of today’s production methods, and we have developed a compact, modular plug & play microalgae photobioreactor that will capture CO₂ emissions continuously and transform it using LED light via photosynthesis into microalgae biomass.”

With the help of BII, we address and identify critical tasks and must-haves to prepare all the material needed for future engagement with investors, risk-mapping, and identifying our main competitors and their strengths and weaknesses. We also learned that becoming a success is not only a matter of great technology but, even more importantly, the quality of the team. Employees are an absolute key to a company’s success.”

— Henrik Busch Larsen
CEO, Algiecel

Get more info



“Aiomic is a health tech company that use AI to optimize healthcare treatments. Our first product is the Surgical Advanced Warning (SAW) system that targets postoperative complications through automated tracking and real-time risk assessment.”

In academia, success parameters often revolve around generating new treatment-relevant data and identifying disease processes. In a start-up, you tend to focus much more on the commercial aspects. The main lessons we have learned at BII is how to improve our business and price models, regulatory and financing strategies, and product and recruitment strategies.”

— Alexander Bonde
CEO, Aiomic

Get more info





BioInnovation
Institute



BII's entrepreneurial environment is shaped and nurtured every day by our employees, start-up teams and everyone who joins us in bringing research to market.



BII

BioInnovation
Institute



Designing the new BII facility

Since BII opened in November 2018 in the COBIS building in central Copenhagen, we have grown and expanded. To accommodate future growth, in 2022 we took important steps by acquiring more space and designing a new BII to better support start-ups and projects in the future.

The new BII domicile is the manifestation of a set of principles and a range of practices supporting collaboration free of barriers.



“With an open building plan, stakeholders at BII are able to move freely throughout our space without having too many walls or doors blocking their way. This, we believe, creates a smoother community transitioning, improving the overall traffic flow for BII guests or family.”

— Thomas Hoffmann
Chief Operating Officer, BII

BII



The new building

An innovative environment is a sustainable environment in itself. That has to be reflected through the choice of materials, greenery and flexible solutions supporting the overall vision of BII.

The new building will provide a natural framework for interaction, enabling the companies to meet in informal as well as formal settings and allowing for cross-pollination between the different projects.



Picture and drawing: Tegnestuen Kontekst.

Creating more laboratory space for future innovation at BII

“When projects are accepted to our programs, we take an early discussion to clarify their needs and prepare a good landing of the projects in the facility when the program starts. The expansion of BII in the coming years will make space for more companies and more scientific disciplines within the building.”

— **Bo Heinemann**
Head of Facility, BII



The BII Main Laboratory is a common workspace where companies are set up next to each other to share experiences, methods and everyday issues.



4 types of laboratories

Creator laboratory

You need a 3D printed prototype, soldering equipment to make your sensor work again or an oscilloscope to measure on your device? These things and more are available in our Creator laboratory.

GMO Class II laboratory

Here you can work with e.g. virus or bacteria that are classified as potentially harmful to the human organism. BII provides a safe working environment and proper destruction facilities.

Cell culture laboratory

We have multiple cell culture laboratories with the equipment you need to carry out your cell structure work in a safe and sterile way.

Fermentation laboratory

You can select and optimize the yield of your strain and ferment cultures up to 1L batches under controlled conditions. This facility is new, and we are continuously expanding with more equipment.





Transforming our
catalyst platform

Educating the next generation of bioentrepreneurs

Education for bioentrepreneurs is of high importance to BII. Education not only helps to raise and develop abilities and competences, but also to support decision-making in a truly interdisciplinary context of research and business.

Summer school

In August, BioInnovation Institute and CBS Executive hosted a one week-long summer school to inspire and teach 36 international postdocs and young researchers in taking great science from the lab to the first investment round.

The students were introduced to key commercial aspects and aspects of planning in relation to innovative projects within human and planetary health. The program offered lectures from CBS Executive, hands-on experience from industry representatives and BII's Business Development team as well as pitch training and advice from highly skilled venture capitalists from BII's network.



Read more about
BII Summer School 2022



Crunches

Co-founder and Managing Partner at Nordic BioVentures Will Wright leads the monthly Crunches for start-ups in Venture Lab. Here, start-ups dive into a specific topic relating to company building, learn new vocabulary, are introduced to new tools and inspiring international speakers and work on case studies. At the end of each Crunch, the start-ups generate an actionable component in their business plan.

"We can see that the Crunches give founders the tools, time and focus to succeed in raising their first millions (DKK) outside the program."

— Will Wright

Co-founder and Managing Partner, Nordic BioVentures



Halos


Executive coach and founder of Today Cecilie Willer leads Halos for start-ups in Venture Lab. A Halo consists of a smaller group of founders that connect and receive support using a combination of tools and resources from the executive coaching world. It enables researchers to grow and cope with the special challenges they face personally and interpersonally when building a business.



Expanding our thriving portfolio


Attracting local and global funding

Over the last 5 years, 55 BII start-ups have attracted no less than EUR 241.7 million, showing that BII business is seen as a unique opportunity with high growth potential.



Additional funding comes in many shapes and sizes

~80% of the reported instances of additional funding are below EUR 1 million and cover ~20% of the additional capital.



Human Health

44 Start-ups

EUR **220.2** million
Additional funding

EUR **81.5** million
Additional funding raised by BII's start-ups in 2022

+

+



Planetary Health

11 Start-ups

EUR **21.5** million
Additional funding

EUR **10.4** million
Additional funding raised by BII's start-ups in 2022

=

=

55 BII start-ups have managed to raise EUR 241.7 million, which is 4.7 times the amount they were awarded by BII in additional funding.

This achievement demonstrates that a relatively small amount of capital, in combination with the network, infrastructure, knowledge and help provided by BII, attract both smaller and larger sums of funding to these businesses - crucial to accelerate their growth.

EUR **241.7** million
Additional funding raised
by BII start-ups 2018–2022

EUR **91.9** million
Additional funding added
to the BII funding in 2022



Expanding our
thriving portfolio

Some success stories from 2022

We cannot possibly mention all the start-up success stories of 2022 because there were so many, but here are some highlights.



Biotech start-up Synklino raised EUR 29.8 million in a Series A investment to advance clinical trials capital raise.

Read more about
Synklino



Food-tech start-up MATR Foods collaborated with the known burger chain Gasoline Grill to also serve plant-based beef in their burgers, made from upcycled sorted out vegetables.

Read more about
MATR Foods



Biotech start-up Evodia raised EUR 4.2 million investment to produce flavours for the beer industry.

Read more about
EvodiaBio



Researchers from Institute of Protein Design at University of Washington US onboarded the Bio Studio program to develop drugs in a new biotech start-up.

Read more about
University of Washington



290+ employees in start-ups and
Bio Studio projects by the end of 2022



Danish biotech platform Enduro Genetics closed first funding round and strengthened team to broadly enable large-scale biological production.

Read more about
Enduro Genetics



Cirque Biomedical entered Research Collaboration and License Agreement with Organon, leading company in Contraceptives.

Read more about
Cirque Biomedical



Digital medico start-up raised EUR 2.4 million for software to patient monitoring.


Read more about
Ward 24/7



Bio Studio will take on projects from European Molecular Biology Laboratory (EMBL) to accelerate promising fundamental research into life-changing innovations.

Read more about
European Molecular Biology Laboratory





Expanding our
thriving portfolio

Cirque's huge license deal with Organon

Organon, a global women's healthcare company, and Cirque Biomedical have entered into a research collaboration and exclusive license agreement for a novel investigational non-hormonal, on-demand contraceptive candidate.

Encouraging preclinical research suggests that Cirque has discovered a method that has the potential to create a temporary barrier to sperm transport by topically reinforcing the existing cervical mucus barrier.

Under the terms of the agreement, Cirque will be responsible for conducting preclinical studies according to the mutually agreed research plan, and is entitled to receive a EUR 9.4 million upfront payment, potential milestone payments of up to EUR 338.4 million and royalties based on net sales.

Cirque Biomedical was launched in 2019 in Copenhagen, Denmark, with backing from BII and later financing from RH Capital, a San Francisco-based impact investor dedicated to women's reproductive health.

"As a leader in contraception, we believe it is critically important to bring forward new options for women, especially in the space of non-hormonal contraceptives, a category preferred by many with limited available options."

Organon is committed to driving innovation across women's health and collaborating with companies like Cirque Biomedical to support early science and bring forward new solutions that address the unmet needs of women."

— Sandra Milligan, M.D.
Head of Research and Development, Organon

See
Cirque Biomedicals
first pitch



CIRQUE
biomedical

Cirque Biomedical is
developing non-hormonal
contraceptive with minimal
side effects.



HEI Therapeutics is developing the world's first medical-grade home monitoring solution for patients with hypothyroidism.



Expanding our thriving portfolio

Maturing an innovative idea in BII's Venture programs

HEI Therapeutics is one of the first start-ups in BII's Venture House program, which is exclusively offered to Venture Lab alumni. In 2022, HEI Therapeutics continued its journey at BII to develop the world's first medical-grade home monitoring solution for patients with hypothyroidism.

Hypothyroidism is a type of thyroid condition in which your thyroid gland doesn't produce enough of certain crucial hormones, resulting in an increased sensitivity to cold, weight gain, tiredness, and depression.

See
HEI Therapeutics
Taking the leap




"I had a friend who needed a different medication when she experienced slower metabolism as a side effect of her cancer treatment," says co-founder Winnie E. Svendsen. "At that time, neither of us understood why it was so difficult to find the right treatment, and it turned out that there are millions of metabolic patients who don't receive proper treatment worldwide, and it is a huge societal problem."

Through different grants from DTU, HEI built scientific data suggesting that they could offer a solution providing better treatment for this group of patients and give them the comfort of self-monitoring to check whether they are correctly medicated, all due to a tiny chip made with patented technology, initially developed at DTU Bioengineering, detecting the thyroid hormone that controls our metabolism.

HEI has experienced strong interest from patients and clinicians in understanding how the patient's

metabolism varies both during a day and over longer periods of time and being better able to correlate that with patient-reported input on symptoms and well-being, which can provide them with a better chance to optimize the patient's treatment plan.





Expanding our thriving portfolio

Early feedback from top investors

Pitching to investors is a fundamental skill to master for any start-up founder. It requires training and fine-tuning again and again, but most entrepreneurs don't have the access to qualified feedback. At BII, first-time and serial entrepreneurs learn to craft a story and get a chance to pitch to top level investors.

"At BII you get training in pitching and become better at telling the company's story in a clear way. Working with the venture capitalists you learn their preferences and can prioritize that in your pitches. We are now familiar with the different investor types and appreciate having the contacts for later follow-ups."

— Andreas Ingemann Jensen
CEO, Tetrakit Technologies




In 2022 BII start-ups delivered more than **100 pitches** for the investor team


"BII introduced us to a range of investors that we would otherwise not have met, and meeting them helped us hone our business case and our pitch."

— Morten Østergaard Andersen
CEO, Bioomix



BII offers a stage to all companies to meet 70+ investors





Broadening outreach,
community & collaborations

Teaming up with top of the class

BII collaborations and partnerships strengthen the life science ecosystem and enhance innovation in different ways.

Helping the industry to foster a more entrepreneurial mindset

A strategic partnership with Novo Nordisk resulted in BII incubating two of their internal projects in our Venture Lab Cohort 3 to help these projects grow and to train the scientists in a safe space to take risks and think differently about how to make new products.

“The collaboration with BII is a new approach and an exciting opportunity for us to engage in entrepreneurship in a less transactional and more informal way that will allow us to connect with the next generation of cutting-edge innovators.”

— **Daniel Timmermann**
VP Innovation Outreach, GDD
Novo Nordisk



Bringing together capacities in women's health

Since the start of the partnership with the Bill & Melinda Gates Foundation in 2021, BII has been actively undertaking activities to understand and strengthen the ecosystem within the area of women's health. A landscape and gap analysis will provide knowledge of the current stage of the research and innovation environment. The Women's Health Innovation Panel, consisting of world-leading academics, VCs, entrepreneurial experts and key industry representatives, was established to accelerate our mission of getting more solutions to address women's health needs and assess women's health start-ups and projects entering Venture Lab and Bio Studio programs.

Together with Medicon Valley Alliance, BII co-hosted the event ‘Gaps and Opportunities in Women's Health’ to zoom in on some of the current problems in the women's health field and discuss how concrete solutions can circumvent this development.

BII | Prize for
Science | Innovation



MIT Professor Benedetto Marelli won the inaugural BII & Science Prize for Innovation Award

In partnership with one of the world's top academic journals, *Science*, BII awarded a new annual innovation prize to recognize bold researchers asking fundamental questions at the intersection of the life sciences and entrepreneurship.

In 2022, more than 60 applications were received around the world, with 3 finalists selected from MIT, John Hopkins Hospital and Mount Sinai- New York. Benedetto Marelli won the award for his research in harnessing silk design to extend the shelf life of staple foods like leafy greens and meats, and to improve crop seeding and growth.

Read more about
BII & Science Prize for Innovation





Broadening outreach,
community & collaborations

Reaching out to the community

In 2022, the BII community has been very active in its outreach activities, including talks, presentations, events and the Venture Lab Demo Day. BII has also managed to establish social media profiles that now have ~18,000 followers.

2022 Pitch Award winners: Ampa Medical

Every year, BII hosts the Venture Lab DemoDay - a celebration and culmination of 12 months of intensive work in the Venture Lab program, where early-stage start-ups have developed the commercial side of their scientific discoveries.

The seven Venture Lab start-ups of 2022 pitched on stage and it was the human health start-up Ampa Medical, that won the Pitch Award. The two co-founders Marie Parslov and Cecilie Ammitzbøll delivered the great pitch that convinced the audience of more than 250 people to cast a vote in their direction.

The start-up, which is a spinout from Rigshospitalet, is developing a new solution for collecting output from ostomies radically different from the stoma bag. Thus, they want to remove time-consuming, mental and physical obstacles related to the current usage of stoma bags, providing a new and better life for people living with a stoma. Congratulations to Ampa Medical!



See the pitch from
DemoDay 2022



SoMe & digital
communications

96K

Number of website visitors

18,617

Followers on social media

2,057

Number of press clippings

54.5%

Increase in LinkedIn followers

Talks and presentations

During 2022, BII and start-ups have delivered talks and presentations all over the world, covering conferences, symposia and workshops. Some were live, some hybrid and some online. The talks included EACR Conference on Cancer Metabolism and Nature Conference Bioengineering Solutions for Biology & Medicine as well as presentations at Nordic Innovation Fair and at the Medicon Valley Alliance Microbiome event.

Inspirational events

BII has an open door policy and seeks to share inspiration, engagement, insights and entrepreneurship among students to encourage a research and entrepreneurial career. One example from December 2022 was when DTU students and researchers were introduced to BII programs and funding opportunities for their start-up projects. 62 student and researchers signed up for the event with representatives from various invited non-academic entities and researchers.

Sign up for BII's
monthly newsletter



BII alumni 2018–2022

Here are just a few of the start-ups we have had the privilege to work with since we opened our doors in 2018. Thanks to you and every BII alumni for your commitment to developing innovative solutions for the benefit of people and society.



BII

Mission

BII's mission is to incubate world-class life science and catalyze its commercialization of new solutions through start-ups by using our knowledge, network, funding and infrastructure.

Vision

BII's vision is to support world-class life science innovation that drives development of new solutions by early life science start-ups for the benefit of people and society.

BII BioInnovation
Institute

BioInnovation Institute Foundation
Ole Maaløes vej 3
DK-2200 Copenhagen N
Denmark

E info@bii.dk
W bii.dk

Produced by the Novo Nordisk Foundation
Impact Department and BioInnovation Institute.

©2023 BioInnovation Institute Foundation
All rights reserved
ISBN 978-87-973974-1-1

An international life
science institute.
We are here to help
you bring your
research to market.



BioInnovation Institute Foundation

Ole Maaløes vej 3

DK 2200 Copenhagen N
Denmark

E info@bii.dk
W bii.dk

ISBN 978-87-973974-1-1